What is JBIO's current stock price?

JBIO (Jade Biosciences, Inc.) is currently trading at $22.21 with a market cap of $724.6M.

What sector is Jade Biosciences, Inc. in?

Jade Biosciences, Inc. (JBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is JBIO a good stock to buy?

Analysts have a Buy consensus on JBIO with a price target of $37.75. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

JBIO Jade Biosciences, Inc.

Healthcare

$22.21-5.33%ClosedMarket Cap: $724.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.33

P/S

0.00

EV/EBITDA

-5.02

DCF Value

$2.74

FCF Yield

-16.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-51.3%

ROA

-40.6%

ROIC

-45.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-40.4M	$—
Q4 null	$0.00	$-31.9M	$—
FY null	$0.00	$-127.4M	$—
Q3 null	$0.00	$-25.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$37.75

Target (Median)

$37.00

Target Range

$32.00 - $45.00

0 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

GuggenheimBuy

2026-05-11

WedbushOutperform

2026-05-11

HC Wainwright & Co.Buy

2026-04-27

HC Wainwright & Co.Buy

2026-03-25

BTIGBuy

2026-03-16

Trading Activity

Insider Trades

View All

King Andrew Jamesofficer: See Remarks

SellFri Feb 13

King Andrew Jamesofficer: See Remarks

SellFri Feb 13

Frohlich Tomdirector, officer: Chief Executive Officer

SellFri Feb 13

Frohlich Tomdirector, officer: Chief Executive Officer

SellFri Feb 13

Dahms Bradford D.officer: Chief Financial Officer

SellFri Feb 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.52

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Peers

SLN